Market Size of Global Urothelial Cancer Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 15.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Urothelial Cancer Drugs Market Analysis
The urothelial cancer drugs market studied is projected to register a CAGR of 15.5% over the forecast period.
The emergence of COVID-19 had a profound impact on the urothelial cancer drugs market. For instance, according to a study published in June 2022, titled "The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands," the number of bladder cancer (BC) diagnoses fell by 14% during the first COVID-19 wave but rose back to pre-COVID-19 levels by the end of 2020 (600 diagnoses a month). Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. Additionally, as per the May 2022 updates from the American Urological Association, during the peak of the COVID-19 pandemic in 2020, more than a quarter of patients with bladder cancer experienced care delays in the United States. As a result of the pandemic, the urothelial cancer drug market and also diagnostics had been significantly impacted. However, due to the increasing number of cancer cases, there will be continuing demand for urothelial cancer drugs.
The urothelial cancer drug market may witness rapid growth also due to the increasing awareness about bladder diseases and available therapies, healthcare expenditure, and the growing burden of bladder cancer. For instance, in March 2022, the 'Don't Go Red' theme for Bladder Cancer Awareness has been declared by the World Bladder Cancer Patient Coalition to raise awareness of warning signs and symptoms, as early detection is critical for enhancing long-term survival and quality of life.
Additionally, the increasing prevalence of bladder cancer across the world supports the market expansion over the forest period. For instance, according to the American Cancer Society, in January 2023, it was estimated that about 82,300 cases of bladder cancer would be reported in the United States, of which 62,400 will be men and 19,900 will be women. Thereby, a high number of bladder cancer cases is going to elevate the need for urothelial cancer drugs. However, side effects associated with drugs are likely to impede market growth.
Urothelial Cancer Drugs Industry Segmentation
As per the scope of the report, urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous bladder tumor that spreads to other parts of the body. The urothelium comprises the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. The Urothelial Cancer Drugs Market has been Segmented by Treatment (Chemotherapy and Immunotherapy) and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment | |
| Chemotherapy | |
| Immunotherapy |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Urothelial Cancer Drugs Market Size Summary
The urothelial cancer drugs market is poised for significant growth, driven by an increasing prevalence of bladder cancer and heightened awareness of bladder diseases and available therapies. The market is expected to expand rapidly due to factors such as rising healthcare expenditure and the growing burden of bladder cancer globally. The COVID-19 pandemic initially disrupted cancer care, leading to delays in diagnosis and treatment, but the demand for urothelial cancer drugs remains strong due to the persistent incidence of the disease. Chemotherapy, particularly the use of drugs like gemcitabine and docetaxel, continues to be a primary treatment modality, with new product launches and advancements in treatment options further propelling market growth.
North America is anticipated to lead the market, supported by a high number of cancer cases and recent drug approvals, including innovative gene therapies. The region's dominance is bolstered by the availability of new treatment options that enhance patient outcomes. The market is characterized by a consolidated landscape, with major players such as Merck & Co. Inc., F Hoffmann-La Roche AG, and AstraZeneca PLC holding significant shares. These companies are actively involved in developing and launching new therapies, contributing to the market's expansion. Despite the challenges posed by drug side effects, the ongoing need for effective urothelial cancer treatments continues to drive market dynamics.
Global Urothelial Cancer Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Emergence and Priority of Targeted Therapy Among Biopharmaceutical Companies
-
1.2.2 Growing Burden of Urothelial Cancer
-
1.2.3 Increasing Awareness on Bladder Diseases and Available Therapies
-
-
1.3 Market Restraints
-
1.3.1 Side Effects Associated with Drugs
-
-
1.4 Industry Attractiveness - Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Buyers/Consumers
-
1.4.2 Bargaining Power of Suppliers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Treatment
-
2.1.1 Chemotherapy
-
2.1.2 Immunotherapy
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Global Urothelial Cancer Drugs Market Size FAQs
What is the current Global Urothelial Cancer Drugs Market size?
The Global Urothelial Cancer Drugs Market is projected to register a CAGR of 15.5% during the forecast period (2024-2029)
Who are the key players in Global Urothelial Cancer Drugs Market?
Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, F Hoffmann-La Roche AG and AstraZeneca PLC are the major companies operating in the Global Urothelial Cancer Drugs Market.
